Effect of Oral JZP-110 (ADX-N05) on Wakefulness and Sleepiness in Adults with Narcolepsy: A Phase 2b Study | Zendy

Chad Ruoff | Zendy; Todd J. Swick | Zendy; Robert C. Doekel | Zendy; Hélène A. Emsellem | Zendy; Neil T. Feldman | Zendy; Russell Rosenberg | Zendy; Gary Bream | Zendy; Moise Khayrallah | Zendy; Yuan Lü | Zendy; Jed Black | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of Oral JZP-110 (ADX-N05) on Wakefulness and Sleepiness in Adults with Narcolepsy: A Phase 2b Study

Author(s) -

Chad Ruoff,

Todd J. Swick,

Robert C. Doekel,

Hélène A. Emsellem,

Neil T. Feldman,

Russell Rosenberg,

Gary Bream,

Moise Khayrallah,

Yuan Lü,

Jed Black

Publication year - 2016

Publication title -

sleep

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.222

H-Index - 207

eISSN - 1550-9109

pISSN - 0161-8105

DOI - 10.5665/sleep.5968

Subject(s) - narcolepsy , wakefulness , modafinil , multiple sleep latency test , medicine , anesthesia , psychology , cataplexy , audiology , excessive daytime sleepiness , psychiatry , insomnia , sleep disorder , electroencephalography

To evaluate the efficacy and safety of oral JZP-110, a second-generation wake-promoting agent with dopaminergic and noradrenergic activity, for treatment of impaired wakefulness and excessive sleepiness in adults with narcolepsy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research